New Publications: Real-World Evidence for Coverage and Formulary DecisionsFriday, 7 December 2018Two articles, published in the Journal of Comparative Effectiveness Research, explore the use of real-world evidence for coverage and formulary decisions. Read more »
New NICE Position Statement – 5L Value Set Still ‘On Hold’Thursday, 29 November 2018NICE has issued a new position statement regarding the use of the EQ-5D-5L value set in evidence submitted to its HTA process. Read more »
EQ-5D-5L Value Set for England Study Team Responds to the EEPRU ReviewThursday, 29 November 2018OHE has published a response to the critique of the EQ-5D-5L value set for England study. Read more »
Approaches, Challenges and Successful Stories of Multi-indication Pricing in EuropeWednesday, 28 November 2018Multi-Indication Pricing: Practical Solutions and Steps to Move Forward. A summary of an HTAi panel session. Read more »
Presentations from ISPOR Europe 2018Friday, 23 November 2018OHE staff recently attended the ISPOR Europe conference in Barcelona. In this blog post, we share a selection of our presentations. Read more »
The WHO Technical Report on the Pricing of Cancer Medicines: Missing a Central Role for Value Assessment
